Can-Fite BioPharma (CANF) Asset Utilization Ratio (2016 - 2023)
Can-Fite BioPharma's (CANF) quarterly Asset Utilization Ratio came in at 0.08 in Q4 2023, up 14.78% YoY from 0.07 in Q4 2022, and up 9.12% on a QoQ basis from 0.07 in Q3 2023.
Can-Fite BioPharma (CANF) Asset Utilization Ratio (2016 - 2023) Analysis & Trends
Can-Fite BioPharma (CANF) has 8 years of Asset Utilization Ratio data on file, last reported at 0.08 in Q4 2023.
- Quarterly Asset Utilization Ratio rose 14.78% year-over-year to 0.08 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was 0.08 (up 14.78% YoY) and the FY2025 annual result came in at 0.04, down 38.38% from the prior year.
- Asset Utilization Ratio improved to 0.08 in Q4 2023, from 0.07 in the prior quarter.
- In the past five years, Asset Utilization Ratio ranged from a high of 0.45 in Q1 2019 to a low of 0.05 in Q1 2022.
- A 5-year average of 0.11 and a median of 0.07 in 2020 frame the typical range for Asset Utilization Ratio.
- Annual changes were most pronounced in 2019 — Asset Utilization Ratio jumped 152.08% — and 2020, when it plunged 67.26%.
- Tracing CANF's Asset Utilization Ratio over 5 years: stood at 0.2 in 2019, then sank by 67.26% to 0.07 in 2020, then fell by 26.79% to 0.05 in 2021, then surged by 38.22% to 0.07 in 2022, then rose by 14.78% to 0.08 in 2023.
- The last three Asset Utilization Ratio figures came in at 0.08 (Q4 2023), 0.07 (Q3 2023), and 0.06 (Q2 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.71 Bn | 131.86 Bn | 2.84 Bn | 0.47 |
| 2 | Regeneron Pharmaceuticals | 86.55 Bn | 78.55 Bn | 3.93 Bn | 0.38 |
| 3 | Argenx Se | 65.26 Bn | 60.07 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.81 Bn | 54.67 Bn | 52.00 Mn | 0.20 |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn | 0.69 |
| 6 | Alnylam Pharmaceuticals | 31.87 Bn | 28.56 Bn | 992.69 Mn | 0.90 |
| 7 | BioNTech SE | 28.13 Bn | 9.74 Bn | 668.28 Mn | 0.13 |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 0.54 |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | 0.13 |
| 10 | Can-Fite BioPharma | 2.77 Mn | -8.78 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 0.08 |
| Sep 30, 2023 | 0.07 |
| Jun 30, 2023 | 0.06 |
| Mar 31, 2023 | 0.06 |
| Dec 31, 2022 | 0.07 |
| Sep 30, 2022 | 0.06 |
| Jun 30, 2022 | 0.05 |
| Mar 31, 2022 | 0.05 |
| Dec 31, 2021 | 0.05 |
| Sep 30, 2021 | 0.07 |
| Jun 30, 2021 | 0.07 |
| Mar 31, 2021 | 0.06 |
| Dec 31, 2020 | 0.07 |
| Sep 30, 2020 | 0.06 |
| Dec 31, 2019 | 0.20 |
| Sep 30, 2019 | 0.17 |
| Jun 30, 2019 | 0.34 |
| Mar 31, 2019 | 0.45 |
| Dec 31, 2018 | 0.41 |
| Sep 30, 2018 | 0.33 |